January 4, 2023

Once again, the free press has been asleep at the wheel.

‘); googletag.cmd.push(function () { googletag.display(‘div-gpt-ad-1609268089992-0’); }); }

Here is another example of how alternative news sources such as internet bloggers are much more useful to the general public than traditional media sources.

A new study out of Germany, funded by the German government, and published in the medical journal Science Immunology, raises the possibility that the so-called vaccine manufactured by BioNTech/Pfizer to fight the mRNA SARS-CoV-2 virus (and possibly the Moderna product), reduces a person’s level of antibodies that fights the virus and increases the level of another kind of antibody that is much less effective at fighting the virus.

First, here are a few basic immunology facts to better understand the new article. 

‘); googletag.cmd.push(function () { googletag.display(‘div-gpt-ad-1609270365559-0’); }); }

According to the Cleveland Clinic:

Antibodies are proteins that protect you when an unwanted substance enters your body.  Produced by your immune system, antibodies bind to these unwanted substances in order to eliminate them from your system.

Another word for antibody is immunoglobulin.

According to Antoine Azar, M.D., Associate Professor of Medicine at Johns Hopkins University, the body makes 5 major types of immunoglobulins: Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Immunoglobulin D and Immunoglobulin E:

Immunoglobulin G (IgG) is the most common type.  IgG has 4 different subclasses, IgG1— 4. IgG is always there to help prevent infections.  It’s also ready to multiply and attack when foreign substances get into the body.  When you don’t have enough, you are more likely to get infections.

The new article is entitled “Class Switch Towards Non-Inflammatory, Spike-Specific IgG4 Antibodies After Repeated SARS-Cov-2 mRNA Vaccination” and was written by Pascal Irrgang and 23 additional authors.  It was published on December 22, 2022 in Science Immunology.  The article states that shortly after the initial two shots of the mRNA SARS-CoV-2 Pfizer product, the level of IgG1 and IgG3 antibodies is increased, but that several months later, the levels of those antibodies decreases and the level of IgG4 antibodies significantly increases.  This effect is exacerbated by a third mRNA shot and/or by a breakthrough infection with the SARS-CoV-2 disease.  The article states that “our results clearly demonstrate that a subsequent infection can further boost IgG4 antibody levels, with IgG4 becoming the most dominant among all anti-spike IgG subclasses in some individuals.”